Early minimally invasive image-guided eNdoscopic evacuation of iNTracerebral hemorrhage: a phase II pilot trial.
Tim Jonas Hallenberger, Urs Fischer, Nilabh Ghosh...
https://pubmed.ncbi.nlm.nih.gov/39628893/Actively Recruiting
Led by University Hospital, Basel, Switzerland · Updated on 2024-07-22
200
Participants Needed
10
Research Sites
52 weeks
Total Duration
This research aims to evaluate the effectiveness of early minimally invasive image-guided hematoma evacuation combined with best medical treatment BMT compared to BMT alone in patients with spontaneous supratentorial intracerebral hemorrhage SSICH. SSICH is a serious form of stroke with poor outcomes and limited treatment improvements from current standard care or traditional surgery. This open-labeled, randomized controlled trial seeks to determine if early endoscopic surgery within 24 hours of bleeding onset can improve functional outcomes at 6 months. Participants are randomly assigned to one of two groups. The intervention group receives BMT plus early minimally invasive endoscopic hematoma evacuation performed within 6 to 24 hours after symptom onset, using advanced imaging and neuro-navigation techniques to guide the surgical procedure. The control group receives best medical treatment alone, which includes strict blood pressure control, seizure prevention, intensive care monitoring, and other guideline-based supportive care. The study involves six visits, with four during hospital stay and two follow-ups as part of routine care. During each visit, assessments include the Glasgow Coma Scale GCS, modified Rankin Scale mRS, and National Institute of Health Stroke Scale NIHSS. Three visits involve CT scans and blood sampling, while other visits assess patient satisfaction, cognition, and quality of life. The primary outcome is functional status measured by mRS at 6 months. Secondary outcomes include mortality rates, cognitive changes, neurological deficits, quality of life, and time spent in intensive care. The trial runs until December 2029 and was designed with patient and public input.
CONDITIONS
Early Minimally Invasive Image Guided Endoscopic Evacuation of Intracerebral Haemorrhage (EMINENT-ICH)
R
Raphael Guzman, Prof. Dr. med.
T
Tim Hallenberger, Dr.
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital, Basel, Switzerland
Lead Sponsor
Swiss National Science Foundation
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 24 hours from symptom onset for surgery and hospital stay for treatment and monitoring
Participants receive either early minimally invasive image guided endoscopic hematoma evacuation as an add-on therapy to best medical treatment (BMT) or best medical treatment alone within 24 hours after symptom onset.
4 visits during hospital stay including assessments and imaging
Duration - Up to 6 months after treatment
Participants attend follow-up visits to assess recovery including functional outcome, cognitive status, quality of life, and patient satisfaction.
2 follow-up visits within clinical routine
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Tim Jonas Hallenberger, Urs Fischer, Nilabh Ghosh...
https://pubmed.ncbi.nlm.nih.gov/39628893/Tim Jonas Hallenberger, Urs Fischer, Leo Hermann Bonati...
https://pubmed.ncbi.nlm.nih.gov/39425219/Tim Jonas Hallenberger, Raphael Guzman, Jehuda Soleman
https://pubmed.ncbi.nlm.nih.gov/35930078/University Hospital, Basel, Switzerland
Lead Sponsor
Swiss National Science Foundation
Collaborating Sponsor